摘要
目的:探讨门冬胰岛素30联合阿卡波糖治疗初诊2型糖尿病患者,患者糖代谢和胰岛β细胞功能的改善情况。方法:选取30例糖化血红蛋白(HbA1c)>8.5%的初诊2型糖尿病患者,在严格饮食控制的基础上予以12周的门冬胰岛素30联合阿卡波糖治疗方案。患者在治疗前后,连续3 d监测指尖血糖,计算平均空腹血糖(FPG)及餐后2 h血糖(PPG),并检测HbA1c;同时进行75 g口服葡萄糖耐量试验,计算胰岛素抵抗指数(HOMA-IR)、胰岛细胞分泌功能指数(HOMA-β),早相胰岛素分泌指数(ΔI30/ΔG30),第二时相胰岛素分泌指数(AUCI)。结果:治疗后,患者血糖控制情况FPG、PPG、HbA1c较治疗前明显降低(P<0.05),HOMA-IR明显改善(P<0.05),HOMA-β和ΔI30/ΔG30均明显提高(P<0.05),AUCI治疗前后无明显变化(P>0.05)。结论:门冬胰岛素30联合阿卡波糖治疗初诊2型糖尿病患者,不仅有效改善糖代谢,而且能保护胰岛β细胞功能,改善早相胰岛素的分泌。
Objective:To study the joint use of insulin aspart 30 combined acarbose treatment in patients with newly diagnosed type 2 diabetes,the glucose metabolism in patients with pancreatic β-cell function and improve the situation.Methods:Selected 30 cases of glycosylated hemoglobin(HbA1c)8.5% of newly diagnosed type 2 diabetes,based on strict diet to be 12 weeks on insulin aspart 30 combined acarbose treatment.Patients before and treatment,fingertip blood glucose monitoring for 3 consecutive days,calculate the average fasting plasma glucose(FPG) and 2 h postprandial glucose(PPG),and detection of HbA1c,simultaneously 75 g oral glucose tolerance test,insulin resistance index(HOMA-IR),islet-cell function index(HOMA-β),early-phase insulin secretion index(△I30/△G30),the second-phase insulin secretion index(AUCI).Results:After treatment,blood glucose control in patients with FPG,PPG,HbA1c was significantly lower than that before treatment(P0.05),HOMA-β and insulin secretion are △I30/△G30 significantly improved compared with before treatment(P0.05),AUCI before and after treatment no significantly change(P0.05).Conclusion:Newly diagnosed type 2 diabetes using insulin aspart 30 combined acarbose combination therapy,not only improve glucose metabolism,but also to protect the β-cell function,improved early-phase insulin secretion.
出处
《南通大学学报(医学版)》
2011年第6期442-444,共3页
Journal of Nantong University(Medical sciences)
基金
南通大学自然科学研究项目资助(10Z082)